Loading
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Latest quote
$179.25
+$2.23 · +1.26%
After-hours
$179.25
$0.00 · 0.00%
Oct 9, 4:12 PM ET
Regular session · ET · Market data may be delayed.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Day range
Current $179.25
52-week range
Current $179.25
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
60
Mixed
Risk
20
Low Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Day range
Current $179.25
52-week range
Current $179.25
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.64B USD | 12.82B USD | 12.14B USD | 11.61B USD | 11.62B USD |
| Cost of goods sold | 9.96B USD | 8.6B USD | 8.32B USD | 8.21B USD | 7.97B USD |
| Gross profit | 3.68B USD | 4.22B USD | 3.82B USD | 3.4B USD | 3.65B USD |
| Selling, general, and administrative | 1.67B USD | 1.54B USD | 1.47B USD | 1.36B USD | 1.2B USD |
| Operating expenses | 1.67B USD | 2.13B USD | 2.22B USD | 2.06B USD | 1.85B USD |
| Interest expense | 549.67M USD | 470.47M USD | 398.55M USD | 357.02M USD | 285.25M USD |
| Depreciation and amortization | 715.35M USD | 723.86M USD | 745.44M USD | 732.6M USD | 680.62M USD |
| Operating income | 2.01B USD | 2.09B USD | 1.6B USD | 1.34B USD | 1.8B USD |
| Net income | 746.8M USD | 936.34M USD | 691.54M USD | 560.4M USD | 978.45M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$235.67
31.48% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 9, 2013 | 2:1 | — | — |
Stock split | Jun 16, 2004 | 3:2 | — | — |
Stock split | Oct 21, 1997 | 5:3 | — | — |
Effective Sep 9, 2013
2:1
Effective Jun 16, 2004
3:2
Effective Oct 21, 1997
5:3
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T11.63B0.01%129.69T JPY0.09%¥122,850+0.12%
Invesco S&P 500 Equal Weight ETFRSP188.8M0.20%96.2B USD0.20%$213.04+0.55%
Vanguard Morningstar Total Stock Market ETFVTI179.76M0.01%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO150M0.01%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB130.08M0.07%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR82.56M0.12%68.2B USD0.05%$234.43+0.22%
iShares Core S&P 500 ETFIVV79.63M0.01%897.2B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY73.5M0.01%821.54B USD0.09%$778.57+0.60%State Street SPDR S&P 500 ETF1557.TInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
